Key result
In a Swiss population-based sample, the prevalence of polypharmacy was 11.8%, and was independently associated with increasing age, body mass index, smoking, and lower education.
Population
4,938 participants of the CoLaus study (53% women, age range 40-81 years) in Switzerland.
Design
Cross-sectional
Authors
Loading...
Polypharmacy affects ~12% of Swiss mid-aged adults; leaves open causal determinants and prevention strategies.
Cross-Sectional (n=4,938)
In a Swiss population-based sample, polypharmacy affects approximately 11.8% of middle-aged and older adults and is strongly associated with older age, obesity, lower education, and smoking.
Castioni et al. (2017) conducted a cross-sectional in Polypharmacy (n=4,938). Risk factors (increasing age, BMI, smoking, lower education) vs. Reference groups (younger age, normal weight, never smokers, higher education) was evaluated on Prevalence of polypharmacy (regular use of ≥5 drugs) (95% CI 10.9-12.6). In a Swiss population-based sample, the prevalence of polypharmacy was 11.8%, and was independently associated with increasing age, body mass index, smoking, and lower education.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: